Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice

Journal of Physiology

Volumn 589, Issue 7, 2011, Pages 1725-1740

  Dries, Jessica L ^a   Kent, Susan D ^a   Virag, Jitka A I ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAG 1 PROTEIN; CD45 ANTIGEN; EPHRIN; EPHRIN A1; EPHRIN A1 FC RECEPTOR FUSION PROTEIN; EPHRIN A2; EPHRIN A3; EPHRIN A4; EPHRIN A6; EPHRIN A7; EPHRIN A8; EPHRIN RECEPTOR A1; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; TROPONIN I; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDITIS; CELL DENSITY; CELL SURVIVAL; CHIMERA; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART DILATATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE WALL; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; LEUKOCYTE COUNT; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SALVAGE THERAPY;

ANIMALS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; EPHRIN-A1; GENE EXPRESSION; IMMUNOGLOBULIN FC FRAGMENTS; MALE; MICE; MICE, 129 STRAIN; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, EPH FAMILY; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TISSUE DISTRIBUTION; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTORS; TROPONIN I;

EID: 79953154439     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2010.202366     Document Type: Article

References (100)

1. + T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. Blood 105, 2869-2876.
2. Abbate A, Biondi-Zoccai GG, Van Tassell BW & Baldi A (2009). Cellular preservation therapy in acute myocardial infarction. Am J Physiol Heart Circ Physiol 296, H563-H565.
3. Arvanitis D & Davy A (2008). Eph/ephrin signaling: networks. Genes Dev 22, 416-429.
4. Bartunek J, Vanderheyden M, Hill J & Terzic A (2010). Cells as biologics for cardiac repair in ischaemic heart failure. Heart 96, 792-800.
5. Bock-Marquette I, Saxena A, White MD, Dimaio JM & Srivastava D (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432, 466-472.
6. Bodor GS, Porterfield D, Voss EM, Smith S & Apple FS (1995). Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem 41, 1710-1715.
7. Brantley-Sieders D, Schmidt S, Parker M & Chen J (2004). Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 10, 3431-3442.
8. Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D & Chen J (2006). Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 66, 10315-10324.
9. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK & Smith SC Jr (2002). ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106, 1893-1900.
10. Bruckner K, Pasquale EB & Klein R (1997). Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science 275, 1640-1643.
11. Chapelle JP (1999). Cardiac troponin I and troponin T: recent players in the field of myocardial markers. Clin Chem Lab Med 37, 11-20.
12. Chen G, Wang Y, Zhou M, Shi H, Yu Z, Zhu Y & Yu F (2010). EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma. Oncol Rep 23, 563-570.
13. Cheng N, Brantley DM & Chen J (2002a). The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 13, 75-85.
14. Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO & Chen J (2002b). Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1, 2-11.
15. Cheng W, Kajstura J, Nitahara JA, Li B, Reiss K, Liu Y, Clark WA, Krajewski S, Reed JC, Olivetti G & Anversa P (1996). Programmed myocyte cell death affects the viable myocardium after infarction in rats. Exp Cell Res 226, 316-327.
16. Contrera JF, Matthews EJ, Kruhlak NL & Benz RD (2004). Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Regul Toxicol Pharmacol 40, 185-206.
17. + T cell population in response to ischemic heart injury. J Immunol 185, 6286-6293.
18. Doong H, Vrailas A & Kohn EC (2002). What's in the 'BAG'?-A functional domain analysis of the BAG-family proteins. Cancer Lett 188, 25-32.
19. Dorn GW 2nd (2009). Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol 6, 283-291.
20. Dorn GW 2nd & Diwan A (2008). The rationale for cardiomyocyte resuscitation in myocardial salvage. J Mol Med 86, 1085-1095.
21. Drummond GB (2009). Reporting ethical matters in The Journal of Physiology: standards and advice. J Physiol 587, 713-719.
22. Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M & Bennett DC (1999). Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 84, 494-501.
23. Edelberg JM, Lee SH, Kaur M, Tang L, Feirt NM, McCabe S, Bramwell O, Wong SC & Hong MK (2002). Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation 105, 608-613.
24. Feuerstein GZ (1999). Apoptosis in cardiac diseases - new opportunities for novel therapeutics for heart diseases. Cardiovasc Drugs Ther 13, 289-294.
25. Fishbein MC, Maclean D & Maroko PR (1978). Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am J Pathol 90, 57-70.
26. Frangogiannis NG (2008). The immune system and cardiac repair. Pharmacol Res 58, 88-111.
27. Frangogiannis NG, Smith CW & Entman ML (2002). The inflammatory response in myocardial infarction. Cardiovasc Res 53, 31-47.
28. Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G & Bauersachs J (2003). Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res 57, 749-756.
29. Freude B, Masters TN, Kostin S, Robicsek F & Schaper J (1998). Cardiomyocyte apoptosis in acute and chronic conditions. Basic Res Cardiol 93, 85-89.
30. Furne C, Ricard J, Cabrera JR, Pays L, Bethea JR, Mehlen P & Liebl DJ (2009). EphrinB3 is an anti-apoptotic ligand that inhibits the dependence receptor functions of EphA4 receptors during adult neurogenesis. Biochim Biophys Acta 1793, 231-238.
31. Gaudron P, Eilles C, Kugler I & Ertl G (1993). Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 87, 755-763.
32. Giaginis C, Tsourouflis G, Zizi-Serbetzoglou A, Kouraklis G, Chatzopoulou E, Dimakopoulou K & Theocharis SE. (2010). Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. Pathol Oncol Res 16, 267-276.
33. Goldstein S, Ali AS & Sabbah H (1998). Ventricular remodeling. Mechanisms and prevention. Cardiol Clin 16, 623-632, vii-viii.
34. Gurusamy N, Lekli I, Gorbunov NV, Gherghiceanu M, Popescu LM & Das DK (2009). Cardioprotection by adaptation to ischaemia augments autophagy in association with BAG-1 protein. J Cell Mol Med 13, 373-387.
35. Haider H, Jiang S, Idris NM & Ashraf M (2008). IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1α/CXCR4 signaling to promote myocardial repair. Circ Res 103, 1300-1308.
36. Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B & Prabhu SD (2011). Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res 89, 129-138.
37. Hassa PO & Hottiger MO (2002). The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-κB in inflammatory disorders. Cell Mol Life Sci 59, 1534-1553.
38. Hausenloy DJ & Yellon DM (2006). Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70, 240-253.
39. Hirai H, Maru Y, Hagiwara K, Nishida J & Takaku F (1987). A novel putative tyrosine kinase receptor encoded by the eph gene. Science 238, 1717-1720.
40. + memory cells stimulates migration. J Leukoc Biol 87, 1059-1068.
41. Holen HL, Shadidi M, Narvhus K, Kjosnes O, Tierens A & Aasheim HC (2008). Signaling through ephrin-A ligand leads to activation of Src-family kinases, Akt phosphorylation, and inhibition of antigen receptor-induced apoptosis. J Leukoc Biol 84, 1183-1191.
42. Holmes JW, Borg TK & Covell JW (2005). Structure and mechanics of healing myocardial infarcts. Annu Rev Biomed Eng 7, 223-253.
43. Hwang H & Kloner RA (2010). Improving regenerating potential of the heart after myocardial infarction: factor-based approach. Life Sci 86, 461-472.
44. Iida H, Honda M, Kawai HF, Yamashita T, Shirota Y, Wang BC, Miao H & Kaneko S (2005). Ephrin-A1 expression contributes to the malignant characteristics of α-fetoprotein producing hepatocellular carcinoma. Gut 54, 843-851.
45. Ivanov AI & Romanovsky AA (2006). Putative dual role of ephrin-Eph receptor interactions in inflammation. IUBMB Life 58, 389-394.
46. Iwanaga K, Takano H, Ohtsuka M, Hasegawa H, Zou Y, Qin Y, Odaka K, Hiroshima K, Tadokoro H & Komuro I (2004). Effects of G-CSF on cardiac remodeling after acute myocardial infarction in swine. Biochem Biophys Res Commun 325, 1353-1359.
47. Jaffe AS (2005). Use of biomarkers in the emergency department and chest pain unit. Cardiol Clin 23, 453-465, vi.
48. Klein R (2001). Excitatory Eph receptors and adhesive ephrin ligands. Curr Opin Cell Biol 13, 196-203.
49. Kullander K & Klein R (2002). Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3, 475-486.
50. Laflamme MA, Zbinden S, Epstein SE & Murry CE (2007). Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu Rev Pathol 2, 307-339.
51. Lambert JM, Lopez EF & Lindsey ML (2008). Macrophage roles following myocardial infarction. Int J Cardiol 130, 147-158.
52. Latronico MV, Costinean S, Lavitrano ML, Peschle C & Condorelli G (2004). Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann N Y Acad Sci 1015, 250-260.
53. Lefer DJ & Granger DN (2000). Oxidative stress and cardiac disease. Am J Med 109, 315-323.
54. MacLellan WR & Schneider MD (1997). Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res 81, 137-144.
55. Mansson-Broberg A, Siddiqui AJ, Genander M, Grinnemo KH, Hao X, Andersson AB, Wardell E, Sylven C & Corbascio M (2008). Modulation of ephrinB2 leads to increased angiogenesis in ischemic myocardium and endothelial cell proliferation. Biochem Biophys Res Commun 373, 355-359.
56. Matsui T, Nagoshi T & Rosenzweig A (2003). Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2, 220-223.
57. Matsui T & Rosenzweig A (2005). Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 38, 63-71.
58. Mellitzer G, Xu Q & Wilkinson DG (1999). Eph receptors and ephrins restrict cell intermingling and communication. Nature 400, 77-81.
59. Meloni M, Caporali A, Graiani G, Lagrasta C, Katare R, Van Linthout S, Spillmann F, Campesi I, Madeddu P, Quaini F & Emanueli C (2010). Nerve growth factor promotes cardiac repair following myocardial infarction. Circ Res 106, 1275-1284.
60. Milavetz JJ, Giebel DW, Christian TF, Schwartz RS, Holmes DR Jr & Gibbons RJ (1998). Time to therapy and salvage in myocardial infarction. J Am Coll Cardiol 31, 1246-1251.
61. Miura T & Miki T (2008). Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 103, 501-513.
62. Miyamoto S, Murphy AN & Brown JH (2009). Akt mediated mitochondrial protection in the heart: metabolic and survival pathways to the rescue. J Bioenerg Biomembr 41, 169-180.
63. Moon JJ, Lee SH & West JL (2007). Synthetic biomimetic hydrogels incorporated with ephrin-A1 for therapeutic angiogenesis. Biomacromolecules 8, 42-49.
64. Muñoz JJ, Alfaro D, García-Ceca J, Alonso-C LM, Jiménez E & Zapata A (2006). Thymic alterations in EphA4-deficient mice. J Immunol 177, 804-813.
65. Murray DB, Gardner JD, Brower GL & Janicki JS (2004). Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats. Am J Physiol Heart Circ Physiol 287, H2295-H2299.
66. Nageh T, Sherwood RA, Harris BM, Byrne JA & Thomas MR (2003). Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention. Int J Cardiol 92, 285-293.
67. Nah DY & Rhee MY (2009). The inflammatory response and cardiac repair after myocardial infarction. Korean Circ J 39, 393-398.
68. Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M, Omiya S, Mizote I, Matsumura Y, Asahi M, Nishida K, Hori M, Mizushima N & Otsu K (2007). The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 13, 619-624.
69. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, et al (1995). Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376, 37-43.
70. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL & Pasquale EB (2000). The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19, 6043-6052.
71. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G & Murcia JM (1998). Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 273, 33533-33539.
72. Oyama MA & Sisson DD (2004). Cardiac troponin-I concentration in dogs with cardiac disease. J Vet Intern Med 18, 831-839.
73. Pandey A, Shao H, Marks RM, Polverini PJ & Dixit VM (1995). Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 268, 567-569.
74. Pasquale EB (2008). Eph-ephrin bidirectional signaling in physiology and disease. Cell 133, 38-52.
75. Pasquale EB (2010). Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10, 165-180.
76. Patten RD & Karas RH (2006). Estrogen replacement and cardiomyocyte protection. Trends Cardiovasc Med 16, 69-75.
77. Pfeffer MA & Braunwald E (1991). Ventricular enlargement following infarction is a modifiable process. Am J Cardiol 68, 127D-131D.
78. Porrello ER & Delbridge LM (2009). Cardiomyocyte autophagy is regulated by angiotensin II type 1 and type 2 receptors. Autophagy 5, 1215-1216.
79. Reed JC, Zha H, Aime-Sempe C, Takayama S & Wang HG (1996). Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv Exp Med Biol 406, 99-112.
80. Segers VF & Lee RT (2010). Protein therapeutics for cardiac regeneration after myocardial infarction. J Cardiovasc Transl Res 3, 469-477.
81. Shaut CA, Saneyoshi C, Morgan EA, Knosp WM, Sexton DR & Stadler HS (2007). HOXA13 directly regulates EphA6 and EphA7 expression in the genital tubercle vascular endothelia. Dev Dyn 236, 951-960.
82. Shujia J, Haider HK, Idris NM, Lu G & Ashraf M (2008). Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc Res 77, 525-533.
83. Siddiqui AJ, Fischer H, Widegren U, Grinnemo KH, Hao X, Mansson-Broberg A, Sylvén C & Gustafsson T (2010). Depressed expression of angiogenic growth factors in the subacute phase of myocardial ischemia: a mechanism behind the remodeling plateau? Coron Artery Dis 21, 65-71.
84. Siragusa M, Katare R, Meloni M, Damilano F, Hirsch E, Emanueli C & Madeddu P (2010). Involvement of phosphoinositide 3-kinase γ in angiogenesis and healing of experimental myocardial infarction in mice. Circ Res 106, 757-768.
85. Slezak J, Tribulova N, Okruhlicova L, Dhingra R, Bajaj A, Freed D & Singal P (2009). Hibernating myocardium: pathophysiology, diagnosis, and treatment. Can J Physiol Pharmacol 87, 252-265.
86. Stadler HS, Higgins KM & Capecchi MR (2001). Loss of Eph-receptor expression correlates with loss of cell adhesion and chondrogenic capacity in Hoxa13 mutant limbs. Development 128, 4177-4188.
87. Tang SC (2002). BAG-1, an anti-apoptotic tumour marker. IUBMB Life 53, 99-105.
88. Terman A & Brunk UT (2005). Autophagy in cardiac myocyte homeostasis, aging, and pathology. Cardiovasc Res 68, 355-365.
89. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS & Dixit VM (1995). Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81, 801-809.
90. Townsend PA, Cutress RI, Carroll CJ, Lawrence KM, Scarabelli TM, Packham G, Stephanou A & Latchman DS (2004). BAG-1 proteins protect cardiac myocytes from simulated ischemia/reperfusion-induced apoptosis via an alternate mechanism of cell survival independent of the proteasome. J Biol Chem 279, 20723-20728.
91. Urbich C, Rossig L & Dimmeler S (2006). Restoration of cardiac function with progenitor cells. Novartis Found Symp 274, 214-223; Discussion 223-217, 272-216.
92. van Rooij E, Marshall WS & Olson EN (2008). Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 103, 919-928.
93. Virag JI, Dries JL, Easton PR, Friesland AM, DeAntonio JH, Chintalgattu V, Cozzi E, Lehman BD, Ding JM & Lust RM (2010). Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2. Am J Physiol Heart Circ Physiol 298, H1088-H1095.
94. Virag JI & Murry CE (2003). Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. Am J Pathol 163, 2433-2440.
95. Wang LF, Fokas E, Juricko J, You A, Rose F, Pagenstecher A, Engenhart-Cabillic R & An HX (2008). Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. BMC Cancer 8, 79.
96. Whelan RS, Kaplinskiy V & Kitsis RN (2010). Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 72, 19-44.
97. Wykosky J & Debinski W (2008). The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 6, 1795-1806.
98. Wykosky J, Gibo DM, Stanton C & Debinski W (2005). EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3, 541-551.
99. Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP & Debinski W (2008). Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 27, 7260-7273.
100. Zhou R (1998). The Eph family receptors and ligands. Pharmacol Ther 77, 151-181.